Clinical Trial Update: A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating lintuzumab (SGN-33) in combination with low-dose cytarabine in patients aged 60 and older with acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Lintuzumab (SGN-33) (lintuzumab)

Snippet

Sponsor: Seagen Inc. | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED